Gen1E’s approach is 10x cheaper and 2x faster, with 2x success-likelihood through focus on rare and neglected diseases with commercial and developmental attractiveness

PIPELINE

GEn1E has a pipeline of products with strong preclinical data. Our lead program is a selective p38α kinase inhibitor, representing a platform for the treatment of various inflammatory and age-related diseases.